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Epidemiologyas type 2 diabetes mellitus, hypertension, dyslipidemia and obesity, have been
associated with an increased risk of cognitive dysfunction, particularly in the elderly. The aim of this
systematic review was to compare these risk factors with regard to the nature and magnitude of the
associated cognitive decrements. Cross-sectional and longitudinal studies that assessed cognitive functioning
in non-demented persons in relation to diabetes/impaired glucose metabolism (k=36), hypertension
(k=24), dyslipidemia (k=7) and obesity (k=6) and that adjusted or matched for age, gender and
education were included. When possible, effect sizes (Cohen's d) were computed per cognitive domain.
Diabetes and hypertension were clearly associated with cognitive decrements; the results for obesity and
dyslipidemia were less consistent. Effect sizes were moderate (median~−0.3) for all risk factors. Decline was
found in all cognitive domains, although the effects on cognitive speed, mental ﬂexibility and memory were
most consistent. Methodological aspects of included studies and implications of these ﬁndings are discussed.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionAs theworld's population gets older, cognitive dysfunctionwill be an
increasing burden for society and health-care resources. Although age
remains the main risk factor for cognitive decline and dementia, it is
increasingly recognized that a substantial number of cases with
dementiamay be attributable to vascular risk factors (i.e. type 2 diabetes
mellitus, hypertension, dyslipidemia, obesity [1–4]), and consequently
these risk factors emerge as major targets for therapeutic intervention.
Although vascular risk factors often co-occur and have shared
consequences, such as atherosclerosis, there are also differences in
their impact on different organ systems. Type 2 diabetes and hyper-
tension, for example, are strongly associated with end-organ damage
in the retina and kidney, through pathophysiological mechanisms that
are at least in part speciﬁc to these conditions [5–8]. For obesity and
dyslipidemia the association with retinal and kidney damage is less
evident [9,10]. This raises the question whether the impact on the
brain, in particular on cognitive functioning, is similar across these
vascular risk factors. Longitudinal population-based studies that assess+31 30 2542100.
an den Berg).
ll rights reserved.the risk of dementia in association with diabetes, hypertension,
dyslipidemia and obesity show that each of these factors is associated
with a relative risk of dementia of approximately 1.5 (systematic
review: [11]). There are, however, also some differences between these
risk factors, particularly with regard to the modulation effect of age at
the time of exposure (e.g. [12,13]). Although dementia is obviously a
highly relevant clinical end-point it should be regarded as a ﬁnal stage
of cerebral damage. Based on the observation that different risk factors
convey a similar risk of dementia, onemay not conclude that the initial
damage associated with each factor is identical. This initial damage,
whichmay be reﬂected in decrements in cognitive functioning short of
dementia, is of particular interest from the viewpoints of pathophy-
siology and prevention. The aim of the present study is therefore to
quantify and compare the proﬁle and size of cognitive decrements
associated with type 2 diabetes, hypertension, dyslipidemia, and
obesity in non-demented persons.
2. Materials and methods
2.1. Identiﬁcation of studies
This systematic review aimed to include all published studies
that examined cognitive functioning associated with type 2 diabetes
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mia or obesity and that met the following inclusion criteria: the
study (1) was published after 1990, (2) had a population-based or
case–control design, (3) matched or adjusted the exposed and the
non-exposed groups for the basic confounders age, sex and edu-
cational level, (4) addressed at least two cognitive domains with
validated neuropsychological tests or, if only one domain was
examined, used at least two different tests on that domain. Studies
that assessed cognitive functioning only with a global screening
instrument, such as the Mini-Mental State Examination, or reported
only a composite measure of cognition were not included. StudiesTable 1a
Description of included studies for type 2 diabetes mellitus and impaired glucose metabolis
Design N % with
risk factor
Age % male R
d
Diabetes
Cross-sectional
Dey et al. [30] C–C 56 50 47 63 H
Fuh et al. [31] C–C 284 25 48 0 H
Ryan et al. [32] C–C 100 50 51 27 H
Van Boxtel et al. [33] P 1360 3 24–81 51 H
Cerhan et al. [14] P 13913 11 45–64 45 H
Cosway et al. [34] C–C 76 50 57 41 H
Vanhanen et al. [35] C–C 83 42 65 43 G
Brands et al. [36] C–C 174 68 66 48 H
Elias et al. [20] P 1811 10 68 ND H
Reaven et al. [37] C–C 59 49 69 59 H
Atiea et al. [38] C–C 40 50 69 68 H
U'ren et al. [39] C–C 38 50 71 16 H
Desmond et al. [18] P 249 12 71 34 H
Kilander et al. [40] P 504 15 72 100 G
Vanhanen et al. [41] P 915 20 73 35 H
van Harten et al. [42] C–C 136 68 73 44 H
Scott et al. [43] P 1131 16 74 42 G
Grodstein et al. [44] P 2374 3 74 0 H
Lindeman et al. [45] P 664 28 74 ND G
Wahlin et al. [46] P 338 9 84 20 H
Longitudinal
Kumari et al. [47] P 5647 5 ~45 72 H
Knopman et al. [22] P 10963 12 47–70 44 H
Fontbonne et al. [48] P 926 6 65 40 H
Kanaya et al. [49] P 999 12 70 40 H
Gregg et al. [50] P 9679 7 72 0 H
Hassing et al. [51] P 274 13 83 29 H
van den Berg et al. [52] P 596 16 85 34 H
Impaired glucose metabolism
Cross-sectional
Fuh et al. [31] C–C 248 27 48 0 G
Vanhanen et al. [53] C–C 83 27 65 43 G
Scott et al. [43] P 1131 16 74 42 G
Lindeman et al. [45] P 664 26 74 ND G
Longitudinal
Kumari et al. [47] P 5647 12 ~45 72 G
Fontbonne et al. [48] P 926 11 65 40 G
Kanaya et al. [49] P 999 25 70 40 G
Vanhanen et al. [54] P 586 14 73 37 G
C–C, case–control design.
P, population-based design.
APOE, apolipoprotein E status.
DM1, type 1 diabetes.
MMSE, Mini-mental State Examination.
GT, glucose tolerance assessed with fasting, or random glucose measurement or formal ora
BP, blood pressure (including systolic blood pressure, history of hypertension, use of antihy
VD, vascular disease (including cerebrovascular disease, stroke, tia, cardiac disease).
DEP, depression (including scores on the Beck Depression Inventory, use of antidepressive m
N/P comorbidity, neurological or psychiatric comorbidity (including epilepsy, Parkinson’s
depression, psychoactive medication such as sedatives, anticonvulsants, substance abuse, m
MD, metabolic disturbances (including hyperlipidemia, thyroid disease, renal failure, system
⁎ All studies were age-, sex- and education-adjusted or -matched, additional adjustmentsthat speciﬁcally involved patients with type 1 diabetes were also not
included.
Medline (1990 to March 2008) and bibliographies from included
papers were used to identify relevant papers. The search was limited to
papers that were written in English and concerned human participants.
We used the search terms (“diabetes”, “hyperglycaemia” or “glucose
tolerance”), (“hypertension” or “blood pressure”), (“dyslipidemia”,
“hypercholesterolemia”, “cholesterol”, “high-density lipoprotein”,
“low-density lipoprotein” or “triglycerides”), (“waist circumference”,
“obesity”, “overweight”, “abdominal fat” or “body-mass index”) in
combination with (“cognitive” or “neuropsychological”) in full orm
isk factor
eﬁnition
Exclusion criteria Additional adjustment/matching⁎
istory Stroke, N/P comorbidity
istory, GT Stroke
istory N/P comorbidity
istory Dementia, N/P comorbidity
istory, GT Stroke, N/P comorbidity, old age ethnicity
istory Stroke, N/P comorbidity, blindness
T Dementia
istory Dementia, N/P comorbidity
istory, GT Stroke, DM1 BP, VD, smoking, alcohol
istory Dementia, stroke, N/P comorbidity
istory Stroke, N/P comorbidity
istory Stroke, N/P comorbidity
istory Stroke
T Not speciﬁed
istory, GT Dementia
istory Stroke, dementia, N/P comorbidity BP
T Not speciﬁed BP, BMI, DEP, estrogen use
istory VD BP, BMI, DEP, vitamin E, hormone
therapy, quality of life
T None DEP, ethnicity
istory, GT Dementia, N/P comorbidity, MD VD
istory, GT Not speciﬁed
istory, GT Stroke
istory, GT MMSEb27
istory, GT Not speciﬁed DEP, APOE, estrogen use
istory Not speciﬁed BP, VD, DEP, smoking, estrogen
use, visual impairment, perceived
health
istory Dementia
istory, GT Not speciﬁed
T Stroke
T Dementia
T Not speciﬁed BP, BMI, DEP, estrogen use
T None DEP, ethnicity
T Note speciﬁed
T MMSEb27
T Not speciﬁed DEP, APOE, estrogen use
T Dementia
l glucose tolerance test using standardized cut-off point.
pertensive medication).
edication, measures of anxiety and stress).
disease, malignancies in central nervous system, sensory of motor neuron disease,
ental retardation, head trauma).
ic disease).
are listed.
Table 1b
Description of included studies for obesity
Design N % with
risk factor
Age % male Risk factor deﬁnition Exclusion criteria Additional adjustment/matching⁎
Cross-sectional
Gunstad et al. [55] P 408 49 33 48 BMI ≥25 kg/m2 N/P comorbidity, MD DEP
Kuo et al. [56] P 2684 38 73 24 BMI ≥30 kg/m2 Dementia, N/P comorbidity,
vision or hearing disability
BP, VD, DM2, MD, ethnicity,
smoking, study site
Dik et al. [16] P 1183 52 75 49 Waist circumferenceN102 cm for men,
N88 cm for women
N65 years old Smoking, alcohol
Longitudinal
Cournot et al. [57] P 2223 20 ~44 49 Quintiles of baseline BMI Dementia BP, DM2, alcohol, perceived health
Wolf et al. [17] P 1814 ND 53 53 Quartiles of BMI and Waist/Hip ratio Stroke, dementia
Elias et al. [58] P 1423 11 76 39 BMI ≥30 kg/m2 Stroke, dementia, VD BP, DM2, MD, alcohol, smoking
P, population-based design.
DM2, type 2 diabetes.
MMSE, Mini-mental State Examination.
BMI, Body-mass Index.
BP, blood pressure (including systolic blood pressure, history of hypertension, use of antihypertensive medication).
VD, vascular disease (including cerebrovascular disease, stroke, tia, cardiac disease).
DEP, depression (including scores on the Beck Depression Inventory, use of antidepressive medication, measures of anxiety and stress).
N/P comorbidity, neurological or psychiatric comorbidity (including epilepsy, Parkinson’s disease, malignancies in central nervous system, sensory of motor neuron disease,
depression, psychoactive medication such as sedatives, anticonvulsants, substance abuse, mental retardation, head trauma).
MD, metabolic disturbances (including hyperlipidemia, thyroid disease, renal failure, systemic disease).
⁎ All studies were age-, sex- and education-adjusted or -matched, additional adjustments are listed.
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eligible papers were collected in full-text versions. RPK and EvdB
independently judged eligible papers according to the inclusion
criteria. In case of disagreement a consensus judgment was made,
together with GJB.
This review focuses on cognitive dysfunction in the absence of
dementia. However, only a subset of the papers that met our
inclusion criteria speciﬁcally mentioned exclusion of demented
subjects in their methods section. More often exclusion of subjects
with dementia or other neurological or mental conditions was
mentioned in more global terms. Table 1a, Table 1b, Table 1c and
Table 1d list the exclusion criteria for individual studies.Table 1c
Description of included studies for dyslipidemia
Design N % with
risk factor
Age %
male
Risk factor deﬁnition
Cross-sectional
Zhang et al. [59] P 4110 ND 37 100 Tertiles of total cholestero
HDL-cholesterol, non-HDL
Dik et al. [16] P 1183 ND 75 49 Triglycerides ≥1.7 mmol/
cholesterol b1.0 (men) //b
Longitudinal
Henderson et al. [60] P 438 ND 49 0 Quartiles of total cholester
HDL-cholesterol and trigly
Teunissen et al. [21] P 144 ND 57 60 Total cholesterol as contin
Komulainen et al. [61] P 101 ND 64 0 HDL cholesterol b50 mg/d
de Frias et al. [62] P 524 ND 67 49 Total cholesterol and trigly
continuous variables
Reitz et al. [63] P 1147 50 76 32 Total cholesterol, HDL cho
cholesterol and triglycerid
continuous variables
P, population-based design.
WHR, waist-to-hip ratio.
APOE, apolipoprotein E status.
VD, vascular disease (including cerebrovascular disease, stroke, tia, cardiac disease).
DEP, depression (including scores on the Beck Depression Inventory, use of antidepressive
N/P comorbidity, neurological or psychiatric comorbidity (including epilepsy, Parkinson’s
depression, psychoactive medication such as sedatives, anticonvulsants, substance abuse, m
⁎ All studies were age-, sex- and education-adjusted or -matched, additional adjustments2.2. Included studies
For diabetes/impaired glucose metabolism the search yielded
1702 hits, 27 of which met our inclusion criteria for diabetes and
9 for impaired glucose metabolism. The search yielded 2406 hits
for hypertension (24 studies were included), 653 hits for
dyslipidemia (7 studies were included) and 1113 hits for obesity
(6 studies were included). Papers that addressed more than one
vascular risk factor were included in multiple risk factor sections
in this review (e.g. [14–18]). When more than one paper
reported on the same population, the paper with the largest
sample size and/or the most detailed information on that riskExclusion criteria Additional adjustment/matching⁎
l,
cholesterol
Stroke WHR, alcohol, physical activity,
diet
l or HDL
1.3 (women) mmol/l
N65 years old smoking, alcohol
ol, LDL-cholesterol,
cerides
Not speciﬁed DEP, medication or estrogen use,
demographics, smoking, alcohol,
exercise
uous variable Stroke, N/P comorbidity
l Not speciﬁed DEP, estrogen use
cerides as Dementia VD
lesterol, LDL
es as
Stroke, dementia, N/P
comorbidity
Ethnicity, APOE
medication, measures of anxiety and stress).
disease, malignancies in central nervous system, sensory of motor neuron disease,
ental retardation, head trauma).
are listed.
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[15,21] or [14,22]).
2.3. Data extraction
2.3.1. Demographics, risk factor, study design
Data on study design, sample size, sex and baseline age were
extracted from the studies and details were included in Tables 1a
through d.When available, the proportion of participants with the risk
factor (e.g. diabetes or hypertension), risk factors deﬁnitions, and the
exclusion criteria of the different studies were extracted. Only studies
with age-, sex-, and education-matched or -adjusted results were
included. Additional adjustments are listed in the ﬁnal column of
Tables 1a through d.
2.3.2. Data analysis
The included studies used variable domain classiﬁcations, which
hampers comparison of the effects between studies. All test scores
were therefore regrouped into the domains general intelligence,Table 1d
Description of included studies for hypertension
Design N % with
risk factor
Age %
male
Risk factor deﬁniti
Cross-sectional
Schmidt et al. [64] C–C 55 64 38 71 History or N160/95
Waldstein et al. [65] C–C 40 50 43 100 ≥140/95 mmHg, u
Van Boxtel [15] P 936 22 24–80 51 ≥140/90 mmHg
Cerhan et al. [14] P 13840 11 45–64 45 ≥160/95 or medic
Andre-Petersson et al. [66] P 500 78 68 100 ≥140/90 (subdivid
stages 1 to 3)
Scherr et al. [67] P 3627 ND ≥65 38 ≥140/90 mmHg
Morris et al. [68] P 5816 55 ≥65 38 History and/or dup
measurement
Desmond et al. [18] P 249 42 71 34 History
Kuusisto et al. [69] P 744 51 73 36 ≥160/95 mmHg o
Dik et al. [16] P 1183 63 75 49 ≥160/90 mmHg o
Harrington et al. [70] C–C 223 48 76 52 N160/90 mmHg, u
Longitudinal
Pavlik et al. [71] P 3270 19 30–59 50 ≥140/90 mmHg o
Swan et al. [72] P 717 5 39–59 100 SBP ≥140 mmHg t
adult life
Elias et al. [73] P 529 64 46 49 ≥140/90 mmHg+
continuous variabl
Swan et al. [74] P 392 15 47 100 SBP ≥140 mmHg
Kilander et al. [75] P 502 ND 50 100 DBP ≤70 mmHg
Wolf et al. [17] P 1814 ND 53 53 ≥140/90 mmHg o
Knopman et al. [22] P 10963 32 47-70 44 ≥140/90 mmHg o
Elias et al. [19] P 1702 ND 55–88 40 ≥160/95 mmHg
Elias et al. [20] P 1811 32 68 ND N160/95 mmHg
Reinprecht et al. [76] P 186 51 68 100 ≥160/90 mmHg o
+ tertiles of DBP
Waldstein et al. [77] P 847 ND 71 59 Duplicate measure
continuous variabl
Hebert et al. [78] P 4284 ND 74 38 Duplicate measure
continuous variabl
Paran et al. [79] P 495 71 77 28 SBP ≥140 mmHg
C–C, case–control design.
P, population-based design.
DM, diabetes mellitus.
SBP, systolic blood pressure.
DBP, diastolic blood pressure.
VD, vascular disease (including cerebrovascular disease, stroke, tia, cardiac disease).
DEP, depression (including scores on the Beck Depression Inventory, use of antidepressive m
N/P comorbidity, neurological or psychiatric comorbidity (including epilepsy, Parkinson's
depression, psychoactive medication such as sedatives, anticonvulsants, substance abuse, m
MD, metabolic disturbances (including hyperlipidemia, thyroid disease, renal failure, system
⁎ All studies were age-, sex- and education-adjusted or -matched, additional adjustmentsmemory, processing speed, attention, cognitive ﬂexibility, percep-
tion/visuoconstruction and language [23] according to a predeﬁned
classiﬁcation of tests per domain, as listed in the appendix. When
available,means and SDswere extracted from the included studies and
converted into Cohen's d as an estimate for effect size [24]. Negative
effect sizes indicate worse cognition in the group with the risk factor.
Median effect sizes per cognitive domain are presented in Table 2a
Table 2b, Table 2c, and Table 2d. In neuropsychological studies, effect
sizes b0.2 are considered small, 0.2–0.8 medium and N0.8 large [24].
The results of studies that did not present data that could be
converted into effect sizes are presented in Table 2 by means of
direction of effect (‘−’ meaning ‘elevated levels of risk factor are
associated with worse cognition’, ‘+’ meaning ‘elevated levels of risk
factor are associated with better cognition or decreased levels of risk
factor are associated with worse cognition (inverse effects)’, ‘+/−’
meaning ‘both elevated and decreased levels of risk factor are
associated with worse cognition (U or J-shaped associations)’, ‘=’
meaning ‘no statistically signiﬁcant association between risk factor
and cognition’). Results from cross-sectional and longitudinal studieson Exclusion criteria Additional adjustment/matching⁎
mmHg Stroke, N/P comorbidity, MD, DM
ntreated VD, N/P comorbidity,
antihypertensive medication
Stroke, dementia, N/P comorbidity
ation Stroke, N/P comorbidity, old age Ethnicity
ed in None
Not speciﬁed VD, DEP, medication use, smoking,
alcohol, perceived health
licate Not speciﬁed Ethnicity
Stroke
r medication Sroke, DM2 Fasting glucose
r medication N65 years old Smoking, alcohol
ntreated Dementia, MD, antihypertensive
medication
r medication Stroke, N/P comorbidity Ethnicity
hroughout Not speciﬁed DEP, VD, antihypertensive
medication
as
es
Stroke, dementia, N/P comorbidity BMI, DEP, alcohol, smoking
VD Stroke
Not speciﬁed
r medication Stroke, dementia
r medication Stroke Ethnicity, psychoactive medication
Stroke Alcohol, smoking
Stroke, DM1 DBP, antihypertensive medication,
VD, smoking, alcohol
r medication None MD, smoking, alcohol
ment,
es
Stroke, dementia, MD Antihypertensive medication, DEP,
alcohol, smoking
ment,
es
Not speciﬁed Ethnicity
Stroke, dementia, N/P comorbidity ‘Chronic conditions’ (unspeciﬁed)
edication, measures of anxiety and stress).
disease, malignancies in central nervous system, sensory of motor neuron disease,
ental retardation, head trauma).
ic disease).
are listed.
Table 2a
Results of included studies for diabetes and impaired glucose metabolism
General
intelligence
Memory Processing
speed
Attention Cognitive
ﬂexibility
Perception/
construction
Language Comment
Diabetes
Cross-sectional
Dey et al. [30] − −⁎ .. −⁎ − .. −
Fuh et al. [31] .. −0.2 −0.2 .. −0.2 .. ..
Ryan et al. [32] −0.4 −0.3 −0.4⁎ −0.6 −0.3 −0.4 ..
Van Boxtel et al. [33] .. −⁎ −⁎ −⁎ −⁎ .. ..
Cerhan et al. [14] .. −⁎ −⁎ .. −⁎ .. ..
Cosway et al. [34] −0.1 −0.1 −0.4 .. −0.3 .. ..
Vanhanen et al. [35] .. −0.7⁎ −1.4⁎ −1.4⁎ −0.6⁎ −0.7 ..
Brands et al. [36] −0.2 −0.3⁎ −0.4⁎ −0.4⁎ −0.3⁎ −0.2 ..
Elias et al. [20] − −⁎ .. .. − − .. Hypertensive DM2 patients were at greatest
risk of cognitive impairment (b25%)
Reaven et al. [37] −0.1 −0.7⁎ −0.7⁎ .. −0.9⁎ .. ..
Atiea et al. [38] −0.4 −0.4 −0.2 −0.5 −0.7 .. ..
U'ren et al. [39] −2.3⁎ −1.2⁎ −0.6 −1.9⁎ −0.3 .. ..
Desmond et al. [18] −0.8⁎ −0.3 .. −0.1 .. −0.5⁎ −0.4
Kilander et al. [40] − − − .. − − .. DM2 was associated with a signiﬁcantly
lower composite z-score
Vanhanen et al. [41] .. 0 −0.4⁎ .. −0.2 .. ..
van Harten et al. [42] .. −0.4 −0.4⁎ .. −0.4⁎ .. ..
Scott et al. [43] .. = .. .. = .. .. No association between DM2 and cognitive
functioning
Grodstein et al. [44] .. −0.2 .. .. −0.2 .. .. DM2 was associated with a signiﬁcantly
lower composite z-score
Lindeman et al. [45] .. −0.1 0 .. −0.1 −0.1 ..
Wahlin et al. [46] .. −0.2⁎ .. .. −0.3⁎ .. .. Largest between-group difference on least
structured tests
Longitudinal
Kumari et al. [47] −⁎ − .. .. − .. −⁎ Baseline DM2 was associated with worse
cognitive performance after 12 years.
Knopman et al. [22] .. − −⁎ .. −⁎ .. .. DM2 was associated with greater decline
over 6 years
Fontbonne et al. [48] − −⁎ −⁎ − −⁎ −⁎ .. DM2 patients had a 1.5 to 2-fold increased
risk of serious worsening (b15%) over
4 years
Kanaya et al. [49] .. .. .. .. −0.2 .. .. DM2was associatedwith signiﬁcant decline
in verbal ﬂuency over 4 years, but only in
women.
Gregg et al. [50] .. .. −0.1⁎ .. −0.1 .. .. DM2 was associated with greater decline
over 3 to 6 years and a twofold increased
risk of impairment (b10%)
Hassing et al. [51] −⁎ −⁎ −⁎ .. .. − .. No baseline differences but DM2 patients
showed greater cognitive decline over
6 years
van den Berg et al. [52] .. − − − .. .. .. DM2 patients was associated with worse
attention and speed at baseline, but not
with accelerated decline over 5 years
Impaired glucose
metabolism
Cross-sectional
Fuh et al. [31] .. 0.1 0.2 .. 0 .. ..
Vanhanen et al. [53] .. −1.0⁎ −1.4⁎ −1.0⁎ −0.9⁎ −0.7 ..
Scott et al. [43] .. − .. .. − .. .. Persons with IGT tended to perform
worse than both DM2 patients and NGT
participants
Lindeman et al. [45] .. 0.1 −0.1 .. −0.1 0.1 ..
Longitudinal
Kumari et al. [47] = = = = = = .. IFG participants did not show greater
cognitive decline over 4 years than NGT
participants.
Fontbonne et al. [48] = = .. .. = .. =
Kanaya et al. [49] .. .. .. .. −0.1 .. ..
Vanhanen et al. [54] .. −0.1 −0.1 .. −0.1 .. ..
Median effect size per domain.
.. cognitive domain not evaluated.
− cognitive domain evaluated, elevated levels of risk factor associated with worse cognition.
+ cognitive domain evaluated, decreased levels of risk factor associated with worse cognition.
+/− cognitive domain evaluated, both elevated and decreased levels of risk factor associated with worse cognition.
= cognitive domain evaluated, no association between risk factor and cognition.
⁎pb0.05.
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Table 2b
Results of included studies for obesity
General
intelligence
Memory Processing
speed
Attention Cognitive
ﬂexibility
Perception/
construction
Language Comment
Cross-sectional
Gunstad et al. [55] .. .. .. −0.1 −0.2⁎ .. ..
Kuo et al. [56] 0.1 0.1 0.1 .. .. .. .. Inverted U-shaped association between BMI
and cognition
Dik et al. [16] − − − .. .. .. ..
Longitudinal
Cournot et al. [57] .. −⁎ −⁎ − .. .. .. Highest quintile BMI associated with worse
cognitive performance at 5y follow-up
Wolf et al. [17] .. −⁎ .. .. −⁎ −⁎ .. Highest baseline quartile of waist/hip ratio,
but not BMI, associated with worse cognitive
performance, particularly in hypertensive
individuals
Elias et al. [58] −0.1 −0.1 .. .. 0 −0.2 .. Obesity was associated with signiﬁcantly worse
cognitive performance, but only in men
Median effect size per domain.
.. cognitive domain not evaluated.
− cognitive domain evaluated, elevated levels of risk factor associated with worse cognition.
+ cognitive domain evaluated, decreased levels of risk factor associated with worse cognition.
+/− cognitive domain evaluated, both elevated and decreased levels of risk factor associated with worse cognition.
= cognitive domain evaluated, no association between risk factor and cognition.
⁎pb0.05.
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fying role of age at the time of exposure the studies are listed
according to age at baseline.
Risk factors in the included studies were mostly dichotomized
(e.g., diabetes yes/no). In a minority of studies the risk factors were
analyzed as continuous variables in statistical analyses. The majority
of studies included both participants who were either treated or
untreated for a particular risk factor. If data on untreated patientswere
available, these were included in the tables.
We did not perform a formal meta-analysis because of the
heterogeneity of risk factor assessment and the variety of assessment
procedures of cognitive functioning, study design (e.g. cross-sec-Table 2c
Results of included studies for dyslipidemia
General
intelligence
Memory Processing
speed
Attention Cognitive
ﬂexibility
Cross-sectional
Zhang et al. [59] .. + +⁎ .. ..
Dik et al. [16] −⁎ −⁎ − .. ..
Longitudinal
Henderson et al. [60] .. +⁎ .. .. ..
Teunissen et al. [21] .. = = = ..
Komulainen et al. [61] .. −⁎ − .. ..
de Frias et al. [62] −⁎ − .. .. −
Reitz et al. [63] .. = .. .. ..
Median effect size per domain.
.. cognitive domain not evaluated.
− cognitive domain evaluated, elevated levels of risk factor associated with worse cognitio
+ cognitive domain evaluated, decreased levels of risk factor associated with worse cogniti
+/− cognitive domain evaluated, both elevated and decreased levels of risk factor associat
= cognitive domain evaluated, no association between risk factor and cognition.
⁎pb0.05.tional/longitudinal or case–control/population-based), and presenta-
tion of the analyses and results (e.g. risk factor presented
dichotomously or as continuous variable, differences in adjustment
for confounding variables).
3. Results
3.1. Methodological aspects
Despite the strict inclusion criteria, the studies included in this
review differed substantially in design and outcome measures. Case–
control studies generally provided limited information about partici-Perception/
construction
Language Comment
.. .. Low total and non-HDL cholesterol associated with
decreased cognitive speed in men
.. .. Low HDL cholesterol, but not high triglycerides was
associated with worse speed and ﬂuid intelligence
.. .. Highest quartile of LDL and increase in LDL and total
cholesterol over 8y associated with better memory
performance
.. .. Total cholesterol was not associated with cognitive
function at baseline or after a 6y follow-up
.. .. Low HDL-cholesterol was associated with increased
risk of poor memory (bmedian) after 12y follow up
− .. High triglyceride levels were associated with greater
10y decline in verbal knowledge. Associations were
strongest for APOE e4 allele carriers.
= = Lipid levels were not associated with 7 year changes
in cognitive function
n.
on.
ed with worse cognition.
Table 2d
Results of included studies for hypertension
General
intelligence
Memory Processing
speed
Attention Cognitive
ﬂexibility
Perception/
construction
Language Comment
Cross-sectional
Schmidt et al. [64] .. −0.9⁎ −0.2 −0.4 .. .. ..
Waldstein et al. [65] .. −2.2⁎ − .. .. .. ..
Van Boxtel [15] .. 0 −0.1 .. −0.1 .. .. Hypertensive participants only showed signiﬁcantly worse
performance on 1 measure of cognitive speed
Cerhan et al. [14] .. −⁎ −⁎ .. −⁎ .. .. Differences were statistically signiﬁcant for women only
Andre-Petersson et al.
[66]
0.2⁎ −0.1⁎ −0.1 .. .. .. .. Blood pressureN180/110 mmHg was associated with
poorer performance, N140−159/90−99 mmHg with
better performance compared to normotensives
Scherr et al. [67] .. = .. = .. .. .. Diastolic blood pressure was not associated with cognitive
function
Morris et al. [68] .. +/− +/− .. .. .. .. Modest inverted U-shape between blood pressure and
cognitive function
Desmond et al. [18] = = .. = .. = = No relation between blood pressure and cognitive function
Kuusisto et al. [69] .. −0.1 .. .. −0.1 .. ..
Dik et al. [16] − = = .. .. .. ..
Harrington et al. [70] .. −0.4⁎ −0.3⁎ −0.8⁎ .. .. ..
Longitudinal
Pavlik et al. [71] .. − − .. .. .. .. Hypertension was only associated with cognitive function
when combined with DM2
Swan et al. [72] .. −⁎ − .. − .. .. Persistent elevated SBP and SBP decrease over 38y
follow-up was associated with worse cognition
Elias et al. [73] −⁎ − − .. .. .. .. High baseline blood pressure was associated with
increased cognitive decline in both young and old
age-groups
Swan et al. [74] .. − −⁎ .. − .. .. High midlife SBP was associated with greater 10-year
decline in cognitive speed
Kilander et al. [75] − − − .. −⁎ − .. High midlife DBP was associated with worse performance,
DBPb70 mmHg was associated with better cognitive
ﬂexibility than normal DBP
Wolf et al. [17] .. −⁎ .. .. −⁎ − .. Hypertension was associated with worse cognitive
performance, particularly in obese individuals
Knopman et al. [22] .. − −⁎ .. − .. .. Baseline blood pressure was associated with greater 6-year
decline in cognitive speed
Elias et al. [19] − −⁎ .. .. − −⁎ ..
Elias et al. [20] − −⁎ .. .. − − .. Hypertensive DM2 patients were at greatest risk of
cognitive impairment (b25%)
Reinprecht et al. [76] −0.4 −0.4⁎ −0.4 .. .. .. .. DBP at age 68 was associated with decreased cognitive
function at age 81
Waldstein et al. [77] .. +/− +/− .. +/− .. +/− U- and J-shaped relation between blood pressure and
cognition.
Hebert et al. [78] .. = = .. .. .. .. Blood pressure was not associated with 6-year cognitive
decline
Paran et al. [79] .. +⁎ .. .. +⁎ .. .. J-shaped relation where normotensives showed worse
cognitive performance than hypertensive individuals
Median effect size per domain.
.. cognitive domain not evaluated.
− cognitive domain evaluated, elevated levels of risk factor associated with worse cognition.
+ cognitive domain evaluated, decreased levels of risk factor associated with worse cognition.
+/− cognitive domain evaluated, both elevated and decreased levels of risk factor associated with worse cognition.
= cognitive domain evaluated, no association between risk factor and cognition.
⁎pb0.05.
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speciﬁcally selected participants who were treated in outpatient
clinics of hospitals, whereas other studies were population-based.
There was also considerable variation in the extent to which co-
morbid conditions (e.g. depression, stroke) and vascular risk factors
other than the studied factor were dealt with. Large population-based
studies generally used less detailed measures of cognitive functioning,
but often assessed possible confounding or interaction effects across
different risk factors more rigorously.
Ten studies on diabetes speciﬁcally excluded participants who had
a stroke. For obesity, dyslipidemia and hypertension these numbers
were 2, 3 and 13, respectively. Eight diabetes-studies speciﬁcally
mentioned exclusion of persons who were demented (at baseline).
For obesity, dyslipidemia and hypertension these numbers were 4, 2
and 6, respectively.3.2. Cognitive functioning
The methods of neuropsychological assessment differed markedly
among the included studies, ranging from an evaluation limited to one
or two cognitive domains to a comprehensive examination across all
major cognitive domains. The three domains that were assessed in
most studies were memory, processing speed and cognitive ﬂexibility.
Memory function was usually assessed by means of a verbal
memory test where participants had to recall a list of unrelated words
that was presented to them repeatedly (Rey Auditory Verbal Learning
Test [25]) or had to recall a short paragraph (WechslerMemory Scale—
Logical Memory [26]). Generally, participants were asked to recall the
words or the text immediately (immediate recall) and/or after a delay
period of 20 to 30 min. Visuospatial memory was assessed in only a
minority (b15%) of studies.Workingmemorywas commonly assessed
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third edition (WAIS-III [27]), where participantswere asked to verbally
repeat series of digits of increasing length in the sameﬁxedorder as the
experimenter or in backward order. Tests of cognitive speed often
included the Digit Symbol Test (WAIS-III) in which participants had to
copy as many symbols according to a code key in 2 min. Cognitive
ﬂexibility was most often assessed by means of the Trail Making Test
Part B [28] that required participants to alternatively connect letters
and digits and Verbal Fluency, where participants are asked to
reproduce as many words as possible that beginwith a speciﬁed letter
of the alphabet over 1 min [29].
3.3. Type 2 diabetes mellitus/impaired glucose metabolism
Twenty-seven included studies [14,18,20,22,30–52] compared
cognitive functioning in patients with type 2 diabetes mellitus to
non-diabetic persons (Table 1a.). Half of the cross-sectional studies
had a case–control design. In the population-based studies diabetes
was most commonly identiﬁed by medical history combined with
fasting or random blood glucose levels (9 out of 17 studies). The
studies generally did not distinguish between type 1 and type 2
diabetes, but given the age of the populations involved the vast
majority of the participants is likely to have had type 2 diabetes
mellitus. The cognitive domains that were assessed most often were
memory (25 studies), processing speed (19 studies) and cognitive
ﬂexibility (24 studies). Language was assessed in three studies only.
Diabetes was associated with statistically signiﬁcant worsening of
cognitive performance in one or more cognitive domains in 13 out of 20
cross-sectional and 5 out of 7 longitudinal studies. The association
between diabetes and cognition differed across the individual domains:
processing speed was signiﬁcantly affected in 63% of studies assessing
that domain, attention in 50%, memory in 44%, cognitive ﬂexibility in
38%, language in 33%, general intelligence in 31% and perception and
construction in 22% of the studies. For the domains most commonly
affected effect sizes ranged from 0 to−1.9, with a median effect size of
−0.4 for processing speed,−0.5 for attention and−0.3 for memory.
The cross-sectional studies in relatively older populations (average
age N65) showed somewhat larger effect sizes than studies with
younger populations. Six studies adjusted their results for the effects
of other vascular risk factors [20,42–44,46,50]. Analyses with or
without these adjustments generally showed similar results.
Eight included studies [31,43,45,47–49,53,54] reported on the
association between impaired glucose metabolism (IGM) short of
diabetes and cognitive functioning (Table 1a.). Two out of 4 cross-
sectional studies had a case–control design. All population-based
studies used an oral glucose tolerance test (OGTT) or fasting blood
glucose to deﬁne impaired glucose metabolism (impaired fasting
glucose (IFG): N6.1 but ≤7.0 mmol/l or impaired glucose tolerance
(IGT): 2 h glucose N7.8 but b11.0 mmol/l). The cognitive domains that
were assessed most often were memory (7 studies), cognitive
ﬂexibility (8 studies) and processing speed (5 studies).
IGM was associated with statistically signiﬁcant worsening of
cognitive performance in 1 out of 4 cross-sectional and none out of 4
longitudinal studies. Effect sizes across the different domains ranged
from−1.4 to 0.2, with a median effect size of−0.1. Interestingly, two
studies showed opposing effects. One cross-sectional study [31]
showed that IGT participants tended to perform better than control
participants and another [43] showed that IGT participants performed
worse than both the control group and the DM2 patients. Only one
study adjusted the result for other vascular risk factors [43]. The
results from this study did not differ from the results of other studies.
3.4. Obesity
Six included studies [16,17,55–58] assessed the association be-
tween obesity and cognitive functioning (Table 1b.), all with apopulation-based design. Five out of six studies used body-mass
indexe (BMI) as a measure of obesity and compared cognitive
performance in participants above a certain cut-off (25 or 30 kg/
m2) or in the highest quartile/quintile to normal-weight individuals.
One study used waist circumference as a measure of obesity. Memory
was assessed most often (5 studies), general intelligence, processing
speed and cognitive ﬂexibility were each assessed in 3 studies.
Obesity was associated with statistically signiﬁcant worsening of
cognitive performance in one or more cognitive domains in 1 out of 3
cross-sectional and 2 out of 3 longitudinal studies. The association
between obesity and cognition differed across the individual domains:
cognitive ﬂexibility was signiﬁcantly affected in 67% of the studies
assessing that domain, perception and construction in 50%, memory in
40%, processing speed in 33% of the studies. General intelligence,
attention and language were affected in none of the studies assessing
those domains. For thedomainsmost commonly affected the effect sizes
range from−0.2 to 0.1, with a median effect size of−0.1 for cognitive
ﬂexibility,−0.2 for perception and construction and 0 for memory.
Studies that assessed obesity at midlife generally showed a more
consistent relation with worse cognitive performance than studies
that assessed obesity at late-life (N65 years). One late-life study
actually reported an inverted U-shaped association showing that both
low and high BMI was associated with worse cognition [56]. Three
studies adjusted their results for the effects of other vascular risk
factors [56–58]. Analyses with or without these adjustments generally
showed similar results.
3.5. Dyslipidemia
Seven studies [16,21,59–63] that assessed the association between
dyslipidemia and cognitive functioning were included (Table 1c.), all
were population-based. Studies on dyslipidemia mostly assessed
serum cholesterol levels (6 studies). Several studies also measured
triglycerides, HDL-cholesterol and LDL-cholesterol. Results were
either expressed dichotomously (4 studies), for example by compar-
ing the highest quartile of cholesterol to the lowest quartile, or
continuously (3 studies), for example per mmol/l or SD increase. The
cognitive domains that were assessed most often were memory (7
studies) and processing speed (4 studies). The other cognitive
domains were assessed in only 1 or two studies.
One out of 2 cross-sectional studies and two out of 5 longitudinal
studies reported a statistically signiﬁcant associationwith one ormore
measures of dyslipidemia and worse cognitive performance. Effect
sizes and the frequency of reported abnormalities could not be
calculated. Two studies actually reported an inverse relation where
low total cholesterol was associated with decreased cognitive speed
[59] and high LDL was associated with better memory performance
[60]. No differences could be observed between different lipid
measures. One study [62] reported an interaction with APOE where
the association between triglyceride level and a decrease in cognitive
functioning over 10 years was strongest in APOE ε4 allele carriers.
The two studies that reported an inverse relation between
dyslipidemia and cognitive functioning assessed cholesterol levels in
midlife. Apart from this observation, no clear differences were found
between the results of midlife and late life studies. Three studies
adjusted their results for the effects of other vascular risk factors
[59,62,63]. Analyses with or without these adjustments generally
showed similar results.
3.6. Hypertension/Blood pressure
Twenty-four studies [14–20,22,64–79] that assessed the associa-
tion between blood pressure and cognitive functioning were included
(Table 2d). Three out of 11 cross-sectional studies and none of the
longitudinal studies had a case–control design. In the population-
based studies hypertension was most commonly deﬁned by means of
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(e.g. N140/90 or 160/95 mmHg; 19 studies). Three studies (also) used
systolic and diastolic blood pressure as continuous variables in the
analysis and expressed the result per SD or 10 mmHg increase. The
cognitive domains that were assessed most often were memory (24
studies), processing speed (16 studies) and cognitive ﬂexibility (12
studies).
Elevated blood pressure was associated with statistically signiﬁ-
cant worsening of cognitive performance in one or more cognitive
domains in 7 out of 11 cross-sectional and 10 out of 13 longitudinal
studies. Two studies [65,68] reported an inverted U-shaped relation
where both high and low blood pressure levels were associated with
worse cognitive performance. One study [79] showed an inverse
relation where normotensive individuals performed worse than
hypertensive persons. The association between blood pressure and
cognition differed across the individual domains: memory was
signiﬁcantly affected in 42% of the studies assessing that domain,
processing speed and general intelligence in 29%, cognitive ﬂexibility
and attention in 25%, perception and construction in 20% of the
studies. Language was affected in none of the studies assessing that
domain. For the domains most commonly affected effect sizes ranged
from 0.2 to−2.2, with a median effect size of−0.4 for memory,−0.1
for general intelligence,−0.2 for processing speed,−0.4 for attention
and −0.1 for cognitive ﬂexibility.
Small differences can be observed between the results of studies
that assessed blood pressure at midlife and at late life: studies that fail
to show an association between elevated blood pressure and cognitive
function or show U-shaped associations were all performed in late life
(N65 years). The size of the effects, however, does not differ between
midlife and late life studies. Nine studies adjusted their results for the
effects of other vascular risk factors [67,69,72–74,76,77,79]. Analyses
with or without these adjustments generally showed similar results.
3.7. Comparison
Comparison of the results over the four vascular risk factors shows
thatmost consistent associationswith cognitive decrements are found
for diabetes (18 of 27 studies) and hypertension (17 of 24 studies).
Results for impaired glucose metabolism obesity and dyslipidemia are
less consistent, with 1 out of 8, 3 out of 6 and 2 out of 5 studies
showing associations with cognitive decrements, respectively. The
cognitive domains most commonly affected (memory, processing
speed and cognitive ﬂexibility) and the effect sizes on affected
domains (median~−0.3) are similar across risk factors.
4. Discussion
In this review the association between type 2 diabetes, obesity,
dyslipidemia, and hypertension and cognitive functioning was
examined. The results show that all four vascular risk factors are
associated with decrements in cognitive functioning, but the associa-
tion was most consistent for type 2 diabetes and hypertension. For
obesity and dyslipidemia a substantial proportion of studies did not
show an association with worse cognitive performance.
Before further discussing these ﬁndings, some methodological
issues regarding the included studies and the approachwe used for our
reviewshould be addressed. Regarding the approach of our review, it is
important to emphasize that we aimed to provide a direct comparison
between vascular risk factors. We therefore aimed to rigorously
standardize inclusion criteria for eligible studies, both with regard to
design as to outcome measures. Where possible, test results from
individual studies were converted to effect sizes and regrouped in pre-
deﬁned cognitive domains. A potential disadvantage of this method is
that a substantial number of studies had to be excluded that did not
meet our criteria. Moreover, studies with negative results may be
underrepresented in this review due to the effects of publication bias.Despite our strict inclusion criteria, the study design of included
studies variedmarkedly, from cross-sectional to longitudinal and from
sampling at population level to recruitment of patients from hospital
clinics. These differences in design lead to differential forms of
selection bias. Whereas hospital-based studies may have been biased
to the recruitment of individualswhose risk factorsweremore difﬁcult
to manage, hence their treatment in a hospital, population-based
studies may have failed to recruit people who were more severely
affected, because theywere lesswilling to participate. Another point of
concern are the exclusion criteria that were applied in the individual
studies. The majority of studies excluded individuals with clinically
manifest cognitive impairments, such as dementia. Obviously, differ-
ences in the way such individuals were identiﬁed and subsequently
excluded leads to variations in the observed effect sizes across studies
and exclusion of persons with more severe cognitive impairments
could potentially lead to underestimation of the effects. The extent in
which co-morbid conditions (e.g. depression, stroke) and vascular risk
factors other than the factor under study were taken into account also
varied greatly. Depression in particular is known to hamper cognitive
functioning and the prevalence of depressionmay vary across different
risk factors. Finally, there are some inherent differences between the
risk factors included in the present review that need to be considered.
Blood glucose, lipid levels, blood pressure and body weight are
essentially continuous variables. Cut-off points that deﬁne diabetes,
dyslipidemia, hypertension and obesity are to some extent arbitrary
and are subject to change over time due to evolving medical insights.
Consequently, the proportion of individuals that is labelled as
“abnormal” varies across risk factors and across time, as can be seen
in Tables 1a through d. It will be evident that the using higher cut-off
points will result in a smaller proportion of individuals who are is
labelled as abnormal and a potentially higher contrast for ﬁnding
effects on cognition. There are also differences in the evolution of the
risk factors throughout the lifespan, with the proportion of individuals
diagnosed with type 2 diabetes increasing sharply after 50 to 60 years
of age, whereas overweight often starts to develop at a much younger
age. Consequently, comparison between risk factors is hampered by
inherent differences in duration and levels of exposure. Despite these
limitations, this paper provides the ﬁrst systematic review that allows
a quantitative comparison between individual vascular risk factors.
The domains of memory, processing speed and cognitive
ﬂexibility were most consistently affected. This proﬁle of cognitive
decrements appears to be rather nonspeciﬁc and resembles the
proﬁle found in normal aging, which is thought to reﬂect a decline in
general-purpose processing resources considered necessary for
efﬁcient cognitive functioning [80]. It should be noted here, however,
that the cognitive domains most commonly affected were also the
domains most frequently assessed. Particularly the domains of
language and perception and construction have been examined in
only a minority of studies.
The size of the cognitive decrements showed remarkable similarity
across risk factors and was generally small to medium, with effect
sizes ranging from −0.1 to −0.5 across cognitive domains and
vascular risk factors. Effect sizes of studies that showed statistically
signiﬁcant associations were about the same size as those of studies
that fail to reach statistical signiﬁcance. This suggests that some of the
studies with negative results had insufﬁcient sample sizes. It is also
important to note that some of the relations between risk factors and
cognition may be nonlinear, in that there may be interaction between
vascular risk factors, or modulation by other factors such as age.
Indeed, for dyslipidemia, obesity and hypertension, but not for
diabetes, several studies show inverse of U-shaped or inverse effects,
where decreased levels of the risk factor were associated with worse
cognitive performance or increased levels were associated with better
performance. These results raise questions about what levels of
certain risk factors may be considered as ‘normal’. In this respect age
may be a modulating factor, although this age effect appears to be less
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that use dementia as an outcome measure [11].
Different vascular risk factors were previously reported to
convey a similar risk of dementia [11]. The present review shows
that early, more subtle cognitive decrements are also largely
similar across vascular risk factors. Imaging studies also show
similar cerebral changes across vascular risk factors, in particular
more accentuated global atrophy and white matter hyperintensities
and an increased occurrence of infarcts, although the magnitude of
the effects may differ across factors [81,82]. Nevertheless, it should
be noted that not all individuals that present with these early
cerebral abnormalities progress to dementia. Therefore, the
cognitive decrements that are reported in the present review do
not necessarily reﬂect a ‘pre-dementia’ stage. Still, these early
changes may represent a window of opportunity for early
intervention studies.
In sum, diabetes and hypertension and, to a lesser extent, obesity
and dyslipidemia are associated with mild to moderate decrements in
cognitive functioning in non-demented persons. The proﬁle of
cognitive decrements is rather nonspeciﬁc, with most consistent
results found in the domains of memory, processing speed and
cognitive ﬂexibility.
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Appendix 1Cognitive domain Included testGeneral intelligence
Crystallised intelligence Verbal IQSimilarities (WAIS)
Vocabulary (WAIS)
Information (WAIS)
Comprehension (WAIS)
National Adult Reading Test
SynonymsFluid intelligence Performal IQ
Picture Completion (WAIS)
Picture Arrangement (WAIS)
Arithmetic (WAIS)
Raven (Colored) Progressive Matrices
Category Test
Alice Heim 4
Identities and Oddities (Mattis DRS)
Word Series, Letter Series, Letter SetsMemory
Working memory Digit Span Forward and Backward(Corsi) Block Span Forward and Backward
Brown–Peterson task
Four-Word Short Term MemoryLearning and Immediate
memory(Rey) Auditory Verbal Learning Test Immediate
Recall
Word List Learning (10, 12, 15, 16 or 20 words)
Immediate Recall
California Verbal Learning Test Immediate Recall
Paired Associate Learning (WMS) Verbal and
Nonverbal Immediate Recall
Logical Memory (WMS) Immediate Recall
Immediate Prose Recall (Rivermead)
Hopkins Verbal Learning Test Related Word Lists
Immediate Recall
Babcock Paragraph Story Recall Immediate
(Buschke) Selective Reminding Test Immediate
Recall
(Russell's) Visual Reproductions Test Immediate
Recall
(Benton) Visual Retention Test Immediate Recall(continued)Appendix 1 (continued)Cognitive domain Included testMemory
Learning and Immediate Visual Reproductions (WMS) Immediate Recall
memory Location Learning Test Immediate RecallRey Complex Figure Test Immediate Recall
(Fuld) Object Learning Test
Picture Recognition Test
Spatial Memory Test
Claeson–Dahl Immediate Recall
East Boston Memory Test Immediate Recall
Bäumler Lern-und Gedächtnistest
Serial Digit Learning Test
Continuous Recognition ParadigmDelayed memory (Rey) Auditory Verbal Learning Test Delayed Recall
Word List Learning (10, 12, 15, 16 or 20 words)
Delayed Recall
California Verbal Learning Test Delayed Recall
Paired Associate Learning (WMS) Verbal and
Nonverbal Delayed Recall
Logical Memory (WMS) Delayed Recall
Delayed Prose Recall (Rivermead)
Hopkins Verbal Learning Test Related Word Lists
Delayed Recall
Babcock Paragraph Story Recall Delayed
(Buschke) Selective Reminding Test Delayed
Recall
(Russell's) Visual Reproductions Test Delayed
Recall
(Benton) Visual Retention Test Delayed Recall
Visual Reproductions (WMS) Delayed Recall
Location Learning Test Delayed Recall
Rey Complex Figure Test Delayed Recall
Claeson–Dahl Delayed Recall
East Boston Memory Test Delayed Recall
Object Memory Delayed RecallProcessing speed
Psychomotor efﬁciency Digit Symbol Substitution (WAIS)Letter Digit Coding/Substitution Test
Symbol Digit Modalities Test
Grooved Pegboard
Perceptual Speed
Choice Reaction Time
Trail Making Test Part A
Useful Field of ViewMotor speed Simple Reaction Time
Finger TappingAttention
Visual attention Stroop Color Word Test Part I and IITarget Finding Task
Sustained attention Digit Vigilance TestD2
Quatember and Maly's Vigilance TestDivided attention Paced Auditory Serial Addition Test
Selective attention Stroop Color Word Test Part IIICognitive ﬂexibility Category Test
Concept Shifting Task
Brixton Spatial Anticipation Test
Wisconsin Card Sorting Test
Verbal Fluency (lexical, category)
Trail Making Test Part B (also C, D and Color)
Serial Subtraction (1's, 3's, 7's)
Austin MazePerception and Construction Tactual Performance Test
Object Assembly (WAIS)
Block Design (WAIS)
Embedded Figures
Rey Complex Figure Copy
(Russell's) Visual Reproductions Test Copy
(Benton) Visual Retention Test Copy
Rosen Figure Drawing Test
Pentagon Drawing
Clock Drawing
Facial Recognition Test
Hooper Visual Organization Test
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Mill Hill
Verbal Meaning Test
Boston Diagnostic Aphasia ExaminationReferences
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